Substance Immunologically Cross-Reactive with Insulin (SICRI) Stimulates Cell Division

Osmak, Maja; Sirotković, M.; Levanat, Sonja; Korbelik, Mladen; Pavelić, Krešimir

doi:10.1159/000226681

Cited by 3 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of SICRI, compared to the effect of insulin obtained under identical experimental in vitro conditions was different. In the same concentration range SICRI exhibits a stimulatory effect, while insulin has an inhibitory effect on the growth of mouse fibroblasts (34] . Our results strongly indicate that murine myeloid leukemia can produce and secrete SICRI which can serve as autocrine tumor-growth regulator.…”

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Substance Immunologically Cross-reactive with Insulin from Murine Myeloid Leukemia: Purification and Characterization

Levanat¹,

Pavelić²

1990

Biological Chemistry Hoppe-Seyler

Self Cite

View full text Add to dashboard Cite

A substance immunologically cross-reactive with insulin (SICRI) appears in murine myeloid leukemia. Progression of disease is paralleled by the increase of SICRI levels in the serum; this increase of SICRI levels did not correlate with a decreased concentration of circulating glucose. SICRI was isolated and purified from spleen infiltrated with leukemic cells. Monospecific antiinsulin immunoglobulin G was used for immunoaffinity chromatography to isolate SICRI from tumor tissue. The purified substance yielded a single band with a molecular mass of about 150 kDa in polyacrylamide gel electrophoresis under denaturating and non-denaturating conditions. Purified SICRI enhanced growth of myeloid leukemia cells in soft agar. Biochemical and biological data together with our previous results obtained in other experimental tumors provide evidence that SICRI and insulin are two distinct biologically active agents. SICRI plays a role in murine myeloid leukemia as an autocrine growth promoting factor. Eine mit Insulin immunologisch kreuzreagierende Substanz bei myeloischer Leukämie der MausZusammenfassung: Bei myeloischer Leukämie der Maus tritt im Blutserum eine mit Insulin immunologisch kreuzreagierende Substanz (SICRI) auf. Mit dem Fortschreiten der Krankheit steigt auch der SICRI-Spiegel im Serum parallel an, der aber nicht mit einer Abnahme der Blutglucose-Konzentration korrelliert ist. Die Substanz wurde aus der Milz, die mit leukämi-schen Zellen infiltriert war, isoliert und gereinigt. Monospezifisches Anti-Insulin-Immunglobulin G diente zur Immunaffinitätschromatographie. Die gereinigte Substanz zeigte in der Polyacrylamid-Gelelektrophorese unter denaturierenden und nicht-denaturierenden Bedingungen eine einzige Bande von ca. 150 kDa. Die gereinigte Substanz stimulierte das Wachstum myeloischer Leukämiezellen in Weichagar. Die biochemischen und biologischen Daten zusammen mit unseren früheren Befunden an anderen experimentellen Tumoren lassen den Schluß zu, daß SICRI und Insulin zwei verschiedene biologisch aktive Stoffe sind. SICRI spielt in der myeloischen Leukämie eine Rolle als autocrinerWachstumsfaktor.

show abstract

Section: Discussionmentioning

confidence: 90%

“…It indicates that SICRI is a potent nonspecific growth factor. The most pronounced stimulatory effect of SICRI on proliferative capacity of cells was observed with cells at GO/GI point of the cell cycle [34] . The effect of SICRI, compared to the effect of insulin obtained under identical experimental in vitro conditions was different.…”

Section: Discussionmentioning

confidence: 95%